P.A.W. Capital’s Iovance Biotherapeutics IOVA Stock Holding History

P.A.W. Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-75,000	Closed	-$1.85M	–	63
2021 Q3	$1.85M	Sell	75,000 -25,000	-25%	-$589K	1.65%	15
2021 Q2	$2.6M	Buy	+100,000	New	+$2.6M	2.18%	14
2016 Q1	–	Sell	-200,000	Closed	-$1.54M	–	66
2015 Q4	$1.54M	Hold	200,000	–	–	1.75%	22
2015 Q3	$1.15M	Buy	200,000 +120,000	+150%	+$935K	1.32%	32
2015 Q2	$734K	Buy	80,000 +15,000	+23%	+$167K	0.74%	45
2015 Q1	$787K	Buy	+65,000	New	+$732K	0.78%	38

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

P.A.W. Capital's IOVA Position: Q4 2021 in Review

P.A.W. Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 75,000 shares — an estimated $1.85M sold.

P.A.W. Capital first reported a position in IOVA in Q1 2015 and held it in 6 quarters. The position peaked at $2.6M in Q2 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

P.A.W. Capital reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
P.A.W. Capital sold 75,000 Iovance Biotherapeutics shares in Q4 2021, an estimated $1.85M.
P.A.W. Capital first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 6 quarters.
P.A.W. Capital's Iovance Biotherapeutics position peaked at $2.6M in Q2 2021.
246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on P.A.W. Capital's 13F filing for Q4 2021, filed 10 Feb 2022.